

MEDICAL ONCOLOGY

PAPER-III

Time: 3 hours
Max. Marks:100

MED ONCO/J/19/17/III

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- a) Staging of neuroblastoma. 3+3+4
 - b) Paraneoplastic syndromes associated with neuroblastoma.
 - c) Management of stage IV neuroblastoma.
- a) Treatment of low risk gestational trophoblastic neoplasm. 4+3+3
 - b) Mixed Mullerian tumour (carcinosarcoma) of uterus.
 - c) Sertoli-Leydig cell tumour of ovary.
- a) How will you evaluate a solitary, large supratentorial brain SOL in a 60-year-old male presenting with neuro-cognitive decline? 5+5
 - b) Management of newly diagnosed primary CNS lymphoma.
- a) Role of autologous PBSCT in Non-Hodgkin's Lymphoma (NHL). 3+3+4
 - b) Conditioning regimes for autologous PBSCT in NHL.
 - c) Acute GVHD (Graft vs Host disease)
- a) Indications of treatment in chronic lymphocytic leukemia (CLL). 3+3+4
 - b) Treatment options in newly diagnosed CLL.
 - c) Management of hairy cell leukemia.
- a) How do you approach abdominal mass on 5-year-old child? 4+3+3
 - b) Staging of Wilms' tumour.
 - c) Management of bilateral Wilms' tumour.

P.T.O.

MEDICAL ONCOLOGY

PAPER-III

- | | | |
|-----|--|-------|
| 7. | a) WHO classification of Myelodysplastic syndrome (MDS).
b) Prognostic scoring systems in MDS.
c) 5q deletion syndrome. | 4+3+3 |
| 8. | a) Diagnostic criteria for Waldenstrom Macroglobulinemia (WM).
b) International Prognostic scoring staging system in WM.
c) Treatment of newly diagnosed WM. | 3+3+4 |
| 9. | a) Management of Ph positive ALL.
b) Role of MRD in ALL treatment.
c) Ph like ALL and its management. | 4+3+3 |
| 10. | a) Systemic therapy for medullary thyroid cancer.
b) Management of radioiodine refractory papillary thyroid carcinoma.
c) Anaplastic thyroid carcinoma. | 4+3+3 |
